Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
700K
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-2.13M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$1.05M
-
Number of sells
-
-15
Significant Holders of TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) as of Q2 2025
15 filings reported holding RNAZ - TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value as of Q2 2025.
TRANSCODE THERAPEUTICS, INC. - Common Stock, $0.0001 par value (RNAZ) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 700K outstanding shares and own 0% of the company stock.
Largest 10 shareholders include Ground Swell Capital, LLC (0 shares), SouthState Corp (0 shares), COMMONWEALTH EQUITY SERVICES, LLC (0 shares), ACADIAN ASSET MANAGEMENT LLC (0 shares), SBI Securities Co., Ltd. (0 shares), Warberg Asset Management LLC (0 shares), CORSAIR CAPITAL MANAGEMENT, L.P. (0 shares), Anson Funds Management LP (0 shares), SABBY MANAGEMENT, LLC (0 shares), and UBS Group AG (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.